nach oben

Cancer and Metastasis Reviews

Erschienen in:

30.09.2023 | Review

Epithelial-to-mesenchymal transition in cancer progression: unraveling the immunosuppressive module driving therapy resistance

verfasst von: Deepti Singh, Hifzur R. Siddique

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Abstract

Cancer cells undergo phenotypic switching (cancer cell plasticity) in response to microenvironmental cues, including exposure to therapy/treatment. Phenotypic plasticity enables the cancer cells to acquire more mesenchymal traits promoting cancer cells’ growth, survival, therapy resistance, and disease recurrence. A significant program in cancer cell plasticity is epithelial-to-mesenchymal transition (EMT), wherein a comprehensive reprogramming of gene expression occurs to facilitate the translational shift from epithelial-to-mesenchymal phenotypes resulting in increased invasiveness and metastasis. In addition, EMT plays a pivotal role in facilitating cancer cells’ escape from the body’s immune system using several mechanisms, such as the downregulation of major histocompatibility complex–mediated antigen presentation, upregulation of immune checkpoint molecules, and recruitment of immune-suppressive cells. Cancer cells’ ability to undergo phenotypic switching and EMT-driven immune escape presents a formidable obstacle in cancer management, highlighting the need to unravel the intricate mechanisms underlying these processes and develop novel therapeutic strategies. This article discusses the role of EMT in promoting immune evasion and therapy resistance. We also discuss the ongoing research on developing therapeutic approaches targeting intrinsic and induced cell plasticity within the immune suppressive microenvironment. We believe this review article will update the current research status and equip researchers, clinicians, and other healthcare professionals with valuable insights enhancing their existing knowledge and shedding light on promising directions for future cancer research. This will facilitate the development of innovative strategies for managing therapy-resistant cancers and improving patient outcomes.

Paksa, A., & Rajagopal, J. (2017). The epigenetic basis of cellular plasticity. Current Opinion In Cell Biology, 49, 116–122.PubMed

Quintanal-Villalonga, A., Taniguchi, H., Zhan, Y. A., Hasan, M. M., Chavan, S. S., Meng, F., Uddin, F., Allaj, V., Manoj, P., Shah, N. S., Chan, J. M., Ciampricotti, M., Chow, A., Offin, M., Ray-Kirton, J., Egger, J. D., Bhanot, U. K., Linkov, I., Asher, M., et al. (2021). Comprehensive molecular characterization of lung tumors implicates AKT and MYC signaling in adenocarcinoma to squamous cell transdifferentiation. Journal of Hematology & Oncology, 14(1), 170.

Saha, S., Mukherjee, S., Khan, P., Kajal, K., Mazumdar, M., Manna, A., Mukherjee, S., De, S., Jana, D., Sarkar, D. K., & Das, T. (2016). Aspirin suppresses the acquisition of chemoresistance in breast cancer by disrupting an NFκB-IL6 signaling axis responsible for the generation of cancer stem cells. Cancer Research, 76(7), 2000–2012.PubMed

Francescangeli, F., Contavalli, P., De Angelis, M. L., Careccia, S., Signore, M., Haas, T. L., Salaris, F., Baiocchi, M., Boe, A., Giuliani, A., Tcheremenskaia, O., Pagliuca, A., Guardiola, O., Minchiotti, G., Colace, L., Ciardi, A., D'Andrea, V., La Torre, F., Medema, J., et al. (2020). A pre-existing population of ZEB2+ quiescent cells with stemness and mesenchymal features dictate chemoresistance in colorectal cancer. Journal of Experimental & Clinical Cancer Research, 39(1), 2.

Boumahdi, S., & de Sauvage, F. J. (2020). The great escape: tumour cell plasticity in resistance to targeted therapy. Nature reviews. Drug Discovery, 19(1), 39–56.PubMed

Shaffer, S. M., Dunagin, M. C., Torborg, S. R., Torre, E. A., Emert, B., Krepler, C., Beqiri, M., Sproesser, K., Brafford, P. A., Xiao, M., Eggan, E., Anastopoulos, I. N., Vargas-Garcia, C. A., Singh, A., Nathanson, K. L., Herlyn, M., & Raj, A. (2017). Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance. Nature, 546(7658), 431–435.PubMedPubMedCentral

Qin, S., Jiang, J., Lu, Y., Nice, E. C., Huang, C., Zhang, J., & He, W. (2020). The emerging role of tumor cell plasticity in modifying therapeutic response. Signal Transduction And Targeted Therapy, 5(1), 228.PubMedPubMedCentral

Cabanos, H. F., & Hata, A. N. (2021). Emerging insights into targeted therapy-tolerant persister cells in cancer. Cancers, 13(11), 2666.PubMedPubMedCentral

Xue, Y., Martelotto, L., Baslan, T., Vides, A., Solomon, M., Mai, T. T., Chaudhary, N., Riely, G. J., Li, B. T., Scott, K., Cechhi, F., Stierner, U., Chadalavada, K., de Stanchina, E., Schwartz, S., Hembrough, T., Nanjangud, G., Berger, M. F., Nilsson, J., et al. (2017). An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer. Nature Medicine, 23(8), 929–937.PubMedPubMedCentral

10.

Singh, D., Khan, M. A., & Siddique, H. R. (2022). Role of p53-miRNAs circuitry in immune surveillance and cancer development: A potential avenue for therapeutic intervention. Seminars in Cell & Developmental Biology, 124, 15–25.

11.

Wei, S. C., Duffy, C. R., & Allison, J. P. (2018). Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discovery, 8(9), 1069–1086.PubMed

12.

Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017). Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell, 168(4), 707–723.PubMedPubMedCentral

13.

Shibue, T., & Weinberg, R. A. (2017). EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nature reviews. Clinical Oncology, 14(10), 611–629.PubMedPubMedCentral

14.

Zhu, X., Chen, L., Liu, L., & Niu, X. (2019). EMT-mediated acquired EGFR-TKI resistance in NSCLC: Mechanisms and strategies. Frontiers In Oncology, 9, 1044.PubMedPubMedCentral

15.

Hass, R., von der Ohe, J., & Ungefroren, H. (2020). The intimate relationship among EMT, MET, and TME: A t(ransdifferentiation) e(nhancing) m(ix) to be exploited for therapeutic purposes. Cancers, 12(12), 3674.PubMedPubMedCentral

16.

De Angelis, M. L., Francescangeli, F., & Zeuner, A. (2019). Breast cancer stem cells as drivers of tumor chemoresistance, dormancy and relapse: New challenges and therapeutic opportunities. Cancers, 11(10), 1569.PubMedPubMedCentral

17.

Culig, Z. (2019). Epithelial mesenchymal transition and resistance in endocrine-related cancers. Biochimica et biophysica acta. Molecular. Cell Research, 1866(9), 1368–1375.

18.

Paulitschke, V., Eichhoff, O., Gerner, C., Paulitschke, P., Bileck, A., Mohr, T., Cheng, P. F., Leitner, A., Guenova, E., Saulite, I., Freiberger, S. N., Irmisch, A., Knapp, B., Zila, N., Chatziisaak, T. P., Stephan, J., Mangana, J., Kunstfeld, R., Pehamberger, H., et al. (2019). Proteomic identification of a marker signature for MAPKi resistance in melanoma. The EMBO Journal, 38(15), e95874.PubMedPubMedCentral

19.

Farmer, P., Bonnefoi, H., Anderle, P., Cameron, D., Wirapati, P., Becette, V., André, S., Piccart, M., Campone, M., Brain, E., Macgrogan, G., Petit, T., Jassem, J., Bibeau, F., Blot, E., Bogaerts, J., Aguet, M., Bergh, J., Iggo, R., & Delorenzi, M. (2009). A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nature Medicine, 15(1), 68–74.PubMed

20.

Luke, J. J., Bao, R., Sweis, R. F., Spranger, S., & Gajewski, T. F. (2019). WNT/β-catenin pathway activation correlates with immune exclusion across human cancers. Clinical Cancer Research, 25(10), 3074–3083.PubMedPubMedCentral

21.

Ruiz de Galarreta, M., Bresnahan, E., Molina-Sánchez, P., Lindblad, K. E., Maier, B., Sia, D., Puigvehi, M., Miguela, V., Casanova-Acebes, M., Dhainaut, M., Villacorta-Martin, C., Singhi, A. D., Moghe, A., von Felden, J., Tal Grinspan, L., Wang, S., Kamphorst, A. O., Monga, S. P., Brown, B. D., et al. (2019). β-Catenin activation promotes immune escape and resistance to anti-PD-1 therapy in hepatocellular carcinoma. Cancer Discovery, 9(8), 1124–1141.PubMed

22.

Singh, D., Khan, M. A., & Siddique, H. R. (2022). Specific targeting of cancer stem cells by immunotherapy: A possible stratagem to restrain cancer recurrence and metastasis. Biochemical Pharmacology, 198, 114955.PubMed

23.

Chen, L., Gibbons, D. L., Goswami, S., Cortez, M. A., Ahn, Y. H., Byers, L. A., Zhang, X., Yi, X., Dwyer, D., Lin, W., Diao, L., Wang, J., Roybal, J., Patel, M., Ungewiss, C., Peng, D., Antonia, S., Mediavilla-Varela, M., Robertson, G., et al. (2014). Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nature Communications, 5, 5241.PubMed

24.

Guinney, J., Dienstmann, R., Wang, X., de Reyniès, A., Schlicker, A., Soneson, C., Marisa, L., Roepman, P., Nyamundanda, G., Angelino, P., Bot, B. M., Morris, J. S., Simon, I. M., Gerster, S., Fessler, E., De Sousa, E., Melo, F., Missiaglia, E., Ramay, H., et al. (2015). The consensus molecular subtypes of colorectal cancer. Nature Medicine, 21(11), 1350–1356.PubMedPubMedCentral

25.

Mak, M. P., Tong, P., Diao, L., Cardnell, R. J., Gibbons, D. L., William, W. N., Skoulidis, F., Parra, E. R., Rodriguez-Canales, J., Wistuba, I. I., Heymach, J. V., Weinstein, J. N., Coombes, K. R., Wang, J., & Byers, L. A. (2016). A patient-derived, pan-cancer EMT signature identifies global molecular alterations and immune target enrichment following epithelial-to-mesenchymal transition. Clinical Cancer Research, 22(3), 609–620.PubMed

26.

Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., Seja, E., Lomeli, S., Kong, X., Kelley, M. C., Sosman, J. A., Johnson, D. B., Ribas, A., & Lo, R. S. (2016). Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell, 165(1), 35–44.PubMedPubMedCentral

27.

Trujillo, J. A., Luke, J. J., Zha, Y., Segal, J. P., Ritterhouse, L. L., Spranger, S., Matijevich, K., & Gajewski, T. F. (2019). Secondary resistance to immunotherapy associated with β-catenin pathway activation or PTEN loss in metastatic melanoma. Journal For Immunotherapy of Cancer, 7(1), 295.PubMedPubMedCentral

28.

Zhan, T., Rindtorff, N., & Boutros, M. (2017). Wnt signaling in cancer. Oncogene, 36(11), 1461–1473.PubMed

29.

Kudo-Saito, C., Shirako, H., Takeuchi, T., & Kawakami, Y. (2009). Cancer metastasis is accelerated through immunosuppression during SNAIL-induced EMT of cancer cells. Cancer Cell, 15(3), 195–206.PubMed

30.

Akalay, I., Janji, B., Hasmim, M., Noman, M. Z., André, F., De Cremoux, P., Bertheau, P., Badoual, C., Vielh, P., Larsen, A. K., Sabbah, M., Tan, T. Z., Keira, J. H., Hung, N. T., Thiery, J. P., Mami-Chouaib, F., & Chouaib, S. (2013). Epithelial-to-mesenchymal transition and autophagy induction in breast carcinoma promote escape from T-cell-mediated lysis. Cancer Research, 73(8), 2418–2427.PubMed

31.

Fernando, R. I., Litzinger, M., Trono, P., Hamilton, D. H., Schlom, J., & Palena, C. (2010). The T-box transcription factor Brachyury promotes epithelial-mesenchymal transition in human tumor cells. The Journal of Clinical Investigation, 120(2), 533–544.PubMedPubMedCentral

32.

Huang, B., Cohen, J. R., Fernando, R. I., Hamilton, D. H., Litzinger, M. T., Hodge, J. W., & Palena, C. (2013). The embryonic transcription factor Brachyury blocks cell cycle progression and mediates tumor resistance to conventional antitumor therapies. Cell Death & Disease, 4(6), e682.

33.

Hamilton, D. H., Huang, B., Fernando, R. I., Tsang, K. Y., & Palena, C. (2014). WEE1 inhibition alleviates resistance to immune attack of tumor cells undergoing epithelial-mesenchymal transition. Cancer Research, 74(9), 2510–2519.PubMedPubMedCentral

34.

David, J. M., Hamilton, D. H., & Palena, C. (2016). MUC1 upregulation promotes immune resistance in tumor cells undergoing brachyury-mediated epithelial-mesenchymal transition. Oncoimmunology, 5(4), e1117738.PubMedPubMedCentral

35.

Terry, S., Buart, S., Tan, T. Z., Gros, G., Noman, M. Z., Lorens, J. B., Mami-Chouaib, F., Thiery, J. P., & Chouaib, S. (2017). Acquisition of tumor cell phenotypic diversity along the EMT spectrum under hypoxic pressure: Consequences on susceptibility to cell-mediated cytotoxicity. Oncoimmunology, 6(2), e1271858.PubMedPubMedCentral

36.

Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., Miller, M. L., Rekhtman, N., Moreira, A. L., Ibrahim, F., Bruggeman, C., Gasmi, B., Zappasodi, R., Maeda, Y., Sander, C., et al. (2015). Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science (New York, N.Y., 348(6230), 124–128.PubMedPubMedCentral

37.

Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D. Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., Saco, J., Homet Moreno, B., Mezzadra, R., Chmielowski, B., Ruchalski, K., Shintaku, I. P., Sanchez, P. J., Puig-Saus, C., Cherry, G., et al. (2016). Mutations associated with acquired resistance to PD-1 blockade in melanoma. The New England Journal of Medicine, 375(9), 819–829.PubMedPubMedCentral

38.

Lu, X., Horner, J. W., Paul, E., Shang, X., Troncoso, P., Deng, P., Jiang, S., Chang, Q., Spring, D. J., Sharma, P., Zebala, J. A., Maeda, D. Y., Wang, Y. A., & DePinho, R. A. (2017). Effective combinatorial immunotherapy for castration-resistant prostate cancer. Nature, 543(7647), 728–732.PubMedPubMedCentral

39.

Skoulidis, F., Goldberg, M. E., Greenawalt, D. M., Hellmann, M. D., Awad, M. M., Gainor, J. F., Schrock, A. B., Hartmaier, R. J., Trabucco, S. E., Gay, L., Ali, S. M., Elvin, J. A., Singal, G., Ross, J. S., Fabrizio, D., Szabo, P. M., Chang, H., Sasson, A., Srinivasan, S., et al. (2018). STK11/LKB1 Mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma. Cancer Discovery, 8(7), 822–835.PubMedPubMedCentral

40.

Xu, J. W., Wang, L., Cheng, Y. G., Zhang, G. Y., Hu, S. Y., Zhou, B., & Zhan, H. X. (2018). Immunotherapy for pancreatic cancer: A long and hopeful journey. Cancer Letters, 425, 143–151.PubMed

41.

Mariathasan, S., Turley, S. J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., Kadel, E. E., III, Koeppen, H., Astarita, J. L., Cubas, R., Jhunjhunwala, S., Banchereau, R., Yang, Y., Guan, Y., Chalouni, C., Ziai, J., Şenbabaoğlu, Y., Santoro, S., Sheinson, D., et al. (2018). TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature, 554(7693), 544–548.PubMedPubMedCentral

42.

Tauriello, D. V. F., Palomo-Ponce, S., Stork, D., Berenguer-Llergo, A., Badia-Ramentol, J., Iglesias, M., Sevillano, M., Ibiza, S., Cañellas, A., Hernando-Momblona, X., Byrom, D., Matarin, J. A., Calon, A., Rivas, E. I., Nebreda, A. R., Riera, A., Attolini, C. S., & Batlle, E. (2018). TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis. Nature, 554(7693), 538–543.PubMed

43.

Datar, I., & Schalper, K. A. (2016). Epithelial-mesenchymal transition and immune evasion during lung cancer progression: The chicken or the egg? Clinical Cancer Research, 22(14), 3422–3424.PubMedPubMedCentral

44.

Lou, Y., Diao, L., Cuentas, E. R., Denning, W. L., Chen, L., Fan, Y. H., Byers, L. A., Wang, J., Papadimitrakopoulou, V. A., Behrens, C., Rodriguez, J. C., Hwu, P., Wistuba, I. I., Heymach, J. V., & Gibbons, D. L. (2016). Epithelial-mesenchymal transition is associated with a distinct tumor microenvironment including elevation of inflammatory signals and multiple immune checkpoints in lung adenocarcinoma. Clinical Cancer Research, 22(14), 3630–3642.PubMedPubMedCentral

45.

Hsu, D. S., Wang, H. J., Tai, S. K., Chou, C. H., Hsieh, C. H., Chiu, P. H., Chen, N. J., & Yang, M. H. (2014). Acetylation of SNAIL modulates the cytokinome of cancer cells to enhance the recruitment of macrophages. Cancer Cell, 26(4), 534–548.PubMed

46.

Dongre, A., Rashidian, M., Eaton, E. N., Reinhardt, F., Thiru, P., Zagorulya, M., Nepal, S., Banaz, T., Martner, A., Spranger, S., & Weinberg, R. A. (2021). Direct and indirect regulators of epithelial-mesenchymal transition-mediated immunosuppression in breast carcinomas. Cancer Discovery, 11(5), 1286–1305.PubMed

47.

Plaschka, M., Benboubker, V., Grimont, M., Berthet, J., Tonon, L., Lopez, J., Le-Bouar, M., Balme, B., Tondeur, G., de la Fouchardière, A., Larue, L., Puisieux, A., Grinberg-Bleyer, Y., Bendriss-Vermare, N., Dubois, B., Caux, C., Dalle, S., & Caramel, J. (2022). ZEB1 transcription factor promotes immune escape in melanoma. Journal for Immunotherapy of Cancer, 10(3), e003484.PubMedPubMedCentral

48.

Katsura, A., Tamura, Y., Hokari, S., Harada, M., Morikawa, M., Sakurai, T., Takahashi, K., Mizutani, A., Nishida, J., Yokoyama, Y., Morishita, Y., Murakami, T., Ehata, S., Miyazono, K., & Koinuma, D. (2017). ZEB1-regulated inflammatory phenotype in breast cancer cells. Molecular Oncology, 11(9), 1241–1262.PubMedPubMedCentral

49.

Taki, M., Abiko, K., Baba, T., Hamanishi, J., Yamaguchi, K., Murakami, R., Yamanoi, K., Horikawa, N., Hosoe, Y., Nakamura, E., Sugiyama, A., Mandai, M., Konishi, I., & Matsumura, N. (2018). SNAIL promotes ovarian cancer progression by recruiting myeloid-derived suppressor cells via CXCR2 ligand upregulation. Nature Communications, 9(1), 1685.PubMedPubMedCentral

50.

Guo, Y., Lu, X., Chen, Y., Rendon, B., Mitchell, R. A., Cuatrecasas, M., Cortés, M., Postigo, A., Liu, Y., & Dean, D. C. (2021). Zeb1 induces immune checkpoints to form an immunosuppressive envelope around invading cancer cells. Science. Advances, 7(21), eabd7455.

51.

Qian, Y., Yao, W., Yang, T., Yang, Y., Liu, Y., Shen, Q., Zhang, J., Qi, W., & Wang, J. (2017). aPKC-ι/P-Sp1/SNAIL signaling induces epithelial-mesenchymal transition and immunosuppression in cholangiocarcinoma. Hepatology (Baltimore, Md.), 66(4), 1165–1182.PubMed

52.

Kuo, C. L., Chou, H. Y., Chiu, Y. C., Cheng, A. N., Fan, C. C., Chang, Y. N., Chen, C. H., Jiang, S. S., Chen, N. J., & Lee, A. Y. (2020). Mitochondrial oxidative stress by Lon-PYCR1 maintains an immunosuppressive tumor microenvironment that promotes cancer progression and metastasis. Cancer Letters, 474, 138–150.PubMed

53.

Ye, L. Y., Chen, W., Bai, X. L., Xu, X. Y., Zhang, Q., Xia, X. F., Sun, X., Li, G. G., Hu, Q. D., Fu, Q. H., & Liang, T. B. (2016). Hypoxia-induced epithelial-to-mesenchymal transition in hepatocellular carcinoma induces an immunosuppressive tumor microenvironment to promote metastasis. Cancer Research, 76(4), 818–830.PubMed

54.

Parajuli, G., Tekguc, M., Wing, J. B., Hashimoto, A., Okuzaki, D., Hirata, T., Sasaki, A., Itokazu, T., Handa, H., Sugino, H., Nishikawa, Y., Metwally, H., Kodama, Y., Tanaka, S., Sabe, H., Yamashita, T., Sakaguchi, S., Kishimoto, T., & Hashimoto, S. (2021). Arid5a promotes immune evasion by augmenting tryptophan metabolism and chemokine expression. Cancer Immunology Research, 9(8), 862–876.PubMed

55.

Wei, C., Yang, C., Wang, S., Shi, D., Zhang, C., Lin, X., Liu, Q., Dou, R., & Xiong, B. (2019). Crosstalk between cancer cells and tumor associated macrophages is required for mesenchymal circulating tumor cell-mediated colorectal cancer metastasis. Molecular Cancer, 18(1), 64.PubMedPubMedCentral

56.

Goyette, M. A., Elkholi, I. E., Apcher, C., Kuasne, H., Rothlin, C. V., Muller, W. J., Richard, D. E., Park, M., Gratton, J. P., & Côté, J. F. (2021). Targeting Axl favors an antitumorigenic microenvironment that enhances immunotherapy responses by decreasing Hif-1α levels. Proceedings of the National Academy of Sciences of the United States of America, 118(29), e2023868118.PubMedPubMedCentral

57.

Yang, C., Dou, R., Wei, C., Liu, K., Shi, D., Zhang, C., Liu, Q., Wang, S., & Xiong, B. (2021). Tumor-derived exosomal microRNA-106b-5p activates EMT-cancer cell and M2-subtype TAM interaction to facilitate CRC metastasis. Molecular Therapy, 29(6), 2088–2107.PubMedPubMedCentral

58.

Hanahan, D., & Coussens, L. M. (2012). Accessories to the crime: Functions of cells recruited to the tumor microenvironment. Cancer Cell, 21(3), 309–322.PubMed

59.

Hui, L., & Chen, Y. (2015). Tumor microenvironment: Sanctuary of the devil. Cancer Letters, 368(1), 7–13.PubMed

60.

Yamaguchi, T., Fushida, S., Yamamoto, Y., Tsukada, T., Kinoshita, J., Oyama, K., Miyashita, T., Tajima, H., Ninomiya, I., Munesue, S., Harashima, A., Harada, S., Yamamoto, H., & Ohta, T. (2016). Tumor-associated macrophages of the M2 phenotype contribute to progression in gastric cancer with peritoneal dissemination. Gastric Cancer, 19(4), 1052–1065.PubMed

61.

Yin, S., Huang, J., Li, Z., Zhang, J., Luo, J., Lu, C., Xu, H., & Xu, H. (2017). The prognostic and clinicopathological significance of tumor-associated macrophages in patients with gastric cancer: A meta-analysis. PloS One, 12(1), e0170042.PubMedPubMedCentral

62.

Yang, M., Li, Z., Ren, M., Li, S., Zhang, L., Zhang, X., & Liu, F. (2018). Stromal infiltration of tumor-associated macrophages conferring poor prognosis of patients with basal-like breast carcinoma. Journal of Cancer, 9(13), 2308–2316.PubMedPubMedCentral

63.

Zhang, Q., He, Y., Luo, N., Patel, S. J., Han, Y., Gao, R., Modak, M., Carotta, S., Haslinger, C., Kind, D., Peet, G. W., Zhong, G., Lu, S., Zhu, W., Mao, Y., Xiao, M., Bergmann, M., Hu, X., Kerkar, S. P., et al. (2019). Landscape and dynamics of single immune cells in hepatocellular carcinoma. Cell, 179(4), 829–845.e20.PubMed

64.

Shrivastava, R., & Shukla, N. (2019). Attributes of alternatively activated (M2) macrophages. Life Sciences, 224, 222–231.PubMed

65.

Mir, F. A., Contreras-Ruiz, L., & Masli, S. (2015). Thrombospondin-1-dependent immune regulation by transforming growth factor-β2-exposed antigen-presenting cells. Immunology, 146(4), 547–556.PubMedPubMedCentral

66.

Dave, M. (2017). TSP-1-mediated induction of T regulatory cell by adipose-derived mesenchymal stem cells: a mechanism of immunosuppression. Digestive Diseases and Sciences, 62(8), 1975–1976.PubMedPubMedCentral

67.

Nath, P. R., Pal-Nath, D., Mandal, A., Cam, M. C., Schwartz, A. L., & Roberts, D. D. (2019). Natural killer cell recruitment and activation are regulated by CD47 expression in the tumor microenvironment. Cancer Immunology Research, 7(9), 1547–1561.PubMedPubMedCentral

68.

Hosseini, H., Obradović, M. M. S., Hoffmann, M., Harper, K. L., Sosa, M. S., Werner-Klein, M., Nanduri, L. K., Werno, C., Ehrl, C., Maneck, M., Patwary, N., Haunschild, G., Gužvić, M., Reimelt, C., Grauvogl, M., Eichner, N., Weber, F., Hartkopf, A. D., Taran, F. A., et al. (2016). Early dissemination seeds metastasis in breast cancer. Nature, 540(7634), 552–558.PubMedPubMedCentral

69.

Dongre, A., Rashidian, M., Reinhardt, F., Bagnato, A., Keckesova, Z., Ploegh, H. L., & Weinberg, R. A. (2017). Epithelial-to-mesenchymal transition contributes to immunosuppression in breast carcinomas. Cancer Research, 77(15), 3982–3989.PubMedPubMedCentral

70.

Terry, S., Savagner, P., Ortiz-Cuaran, S., Mahjoubi, L., Saintigny, P., Thiery, J. P., & Chouaib, S. (2017). New insights into the role of EMT in tumor immune escape. Molecular Oncology, 11(7), 824–846.PubMedPubMedCentral

71.

Rückerl, D., & Allen, J. E. (2014). Macrophage proliferation, provenance, and plasticity in macroparasite infection. Immunological Reviews, 262(1), 113–133.PubMedPubMedCentral

72.

Zhu, J., Zhi, Q., Zhou, B. P., Tao, M., Liu, J., & Li, W. (2016). The role of tumor associated macrophages in the tumor microenvironment: Mechanism and functions. Anti-Cancer Agents In Medicinal Chemistry, 16(9), 1133–1141.PubMed

73.

Helm, O., Held-Feindt, J., Grage-Griebenow, E., Reiling, N., Ungefroren, H., Vogel, I., Krüger, U., Becker, T., Ebsen, M., Röcken, C., Kabelitz, D., Schäfer, H., & Sebens, S. (2014). Tumor-associated macrophages exhibit pro- and anti-inflammatory properties by which they impact on pancreatic tumorigenesis. International Journal of Cancer, 135(4), 843–861.PubMed

74.

Mishra, A. K., Banday, S., Bharadwaj, R., Ali, A., Rashid, R., Kulshreshtha, A., & Malonia, S. K. (2022). Macrophages as a potential immunotherapeutic target in solid cancers. Vaccines, 11(1), 55.PubMedPubMedCentral

75.

Coussens, L. M., & Werb, Z. (2002). Inflammation and cancer. Nature, 420(6917), 860–867.PubMedPubMedCentral

76.

Pinto, M. L., Rios, E., Durães, C., Ribeiro, R., Machado, J. C., Mantovani, A., Barbosa, M. A., Carneiro, F., & Oliveira, M. J. (2019). The two faces of tumor-associated macrophages and their clinical significance in colorectal cancer. Frontiers in Immunology, 10, 1875.PubMedPubMedCentral

77.

Bonde, A. K., Tischler, V., Kumar, S., Soltermann, A., & Schwendener, R. A. (2012). Intratumoral macrophages contribute to epithelial-mesenchymal transition in solid tumors. BMC Cancer, 12, 35.PubMedPubMedCentral

78.

Shahbaz, S., Bozorgmehr, N., Koleva, P., Namdar, A., Jovel, J., Fava, R. A., & Elahi, S. (2018). CD71+VISTA+ erythroid cells promote the development and function of regulatory T cells through TGF-β. PLoS Biology, 16(12), e2006649.PubMedPubMedCentral

79.

Hao, Y., Baker, D., & Ten Dijke, P. (2019). TGF-β-mediated epithelial-mesenchymal transition and cancer metastasis. International Journal of Molecular Sciences, 20(11), 2767.PubMedPubMedCentral

80.

Liu, M., Li, S., & Li, M. O. (2018). TGF-β control of adaptive immune tolerance: A break from Treg cells. Bioessays : News and Reviews In Molecular, Cellular And Developmental Biology, 40(11), e1800063.PubMed

81.

Crane, C. A., Han, S. J., Barry, J. J., Ahn, B. J., Lanier, L. L., & Parsa, A. T. (2010). TGF-beta downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients. Neuro-oncology, 12(1), 7–13.PubMed

82.

Viel, S., Marçais, A., Guimaraes, F. S., Loftus, R., Rabilloud, J., Grau, M., Degouve, S., Djebali, S., Sanlaville, A., Charrier, E., Bienvenu, J., Marie, J. C., Caux, C., Marvel, J., Town, L., Huntington, N. D., Bartholin, L., Finlay, D., Smyth, M. J., & Walzer, T. (2016). TGF-β inhibits the activation and functions of NK cells by repressing the mTOR pathway. Science Signaling, 9(415), ra19.PubMed

83.

Gregory, P. A., Bracken, C. P., Smith, E., Bert, A. G., Wright, J. A., Roslan, S., Morris, M., Wyatt, L., Farshid, G., Lim, Y. Y., Lindeman, G. J., Shannon, M. F., Drew, P. A., Khew-Goodall, Y., & Goodall, G. J. (2011). An autocrine TGF-beta/ZEB/miR-200 signaling network regulates establishment and maintenance of epithelial-mesenchymal transition. Molecular Biology of the Cell, 22(10), 1686–1698.PubMedPubMedCentral

84.

David, J. M., Dominguez, C., McCampbell, K. K., Gulley, J. L., Schlom, J., & Palena, C. (2017). A novel bifunctional anti-PD-L1/TGF-β Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells. Oncoimmunology, 6(10), e1349589.PubMedPubMedCentral

85.

Zhu, P., Baek, S. H., Bourk, E. M., Ohgi, K. A., Garcia-Bassets, I., Sanjo, H., Akira, S., Kotol, P. F., Glass, C. K., Rosenfeld, M. G., & Rose, D. W. (2006). Macrophage/cancer cell interactions mediate hormone resistance by a nuclear receptor derepression pathway. Cell, 124(3), 615–629.PubMed

86.

Izumi, K., Fang, L. Y., Mizokami, A., Namiki, M., Li, L., Lin, W. J., & Chang, C. (2013). Targeting the androgen receptor with siRNA promotes prostate cancer metastasis through enhanced macrophage recruitment via CCL2/CCR2-induced STAT3 activation. EMBO Molecular Medicine, 5(9), 1383–1401.PubMedPubMedCentral

87.

Antony, J., & Huang, R. Y. (2017). AXL-Driven EMT state as a targetable conduit in cancer. Cancer Research, 77(14), 3725–3732.PubMed

88.

Santamaria, P. G., Moreno-Bueno, G., Portillo, F., & Cano, A. (2017). EMT: Present and future in clinical oncology. Molecular Oncology, 11(7), 718–738.PubMedPubMedCentral

89.

Terry, S., Abdou, A., Engelsen, A. S. T., Buart, S., Dessen, P., Corgnac, S., Collares, D., Meurice, G., Gausdal, G., Baud, V., Saintigny, P., Lorens, J. B., Thiery, J. P., Mami-Chouaib, F., & Chouaib, S. (2019). AXL targeting overcomes human lung cancer cell resistance to NK- and CTL-mediated cytotoxicity. Cancer Immunology Research, 7(11), 1789–1802.PubMed

90.

Xiong, X., Liao, X., Qiu, S., Xu, H., Zhang, S., Wang, S., Ai, J., & Yang, L. (2022). CXCL8 in tumor biology and its implications for clinical translation. Frontiers in Molecular Biosciences, 9, 723846.PubMedPubMedCentral

91.

Cheng, Y., Ma, X. L., Wei, Y. Q., & Wei, X. W. (2019). Potential roles and targeted therapy of the CXCLs/CXCR2 axis in cancer and inflammatory diseases. Biochimica et Biophysica Acta. Reviews on. Cancer, 1871(2), 289–312.

92.

Serafini, P., Mgebroff, S., Noonan, K., & Borrello, I. (2008). Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Research, 68(13), 5439–5449.PubMedPubMedCentral

93.

Hanson, E. M., Clements, V. K., Sinha, P., Ilkovitch, D., & Ostrand-Rosenberg, S. (2009). Myeloid-derived suppressor cells down-regulate L-selectin expression on CD4+ and CD8+ T cells. Journal of Immunology (Baltimore, Md.: 1950), 183(2), 937–944.PubMed

94.

Geis-Asteggiante, L., Belew, A. T., Clements, V. K., Edwards, N. J., Ostrand-Rosenberg, S., El-Sayed, N. M., & Fenselau, C. (2018). Differential content of proteins, mRNAs, and miRNAs suggests that MDSC and their exosomes may mediate distinct immune suppressive functions. Journal of Proteome Research, 17(1), 486–498.PubMed

95.

Mao, F. Y., Zhao, Y. L., Lv, Y. P., Teng, Y. S., Kong, H., Liu, Y. G., Wu, X. L., Hao, C. J., Chen, W., Duan, M. B., Han, B., Ma, Q., Wang, T. T., Peng, L. S., Zhang, J. Y., Cheng, P., Su, C. Y., Fu, X. L., Zou, Q. M., et al. (2018). CD45⁺CD33^lowCD11b^dim myeloid-derived suppressor cells suppress CD8⁺ T cell activity via the IL-6/IL-8-arginase I axis in human gastric cancer. Cell Death & Disease, 9(7), 763.

96.

Chi, N., Tan, Z., Ma, K., Bao, L., & Yun, Z. (2014). Increased circulating myeloid-derived suppressor cells correlate with cancer stages, interleukin-8 and -6 in prostate cancer. International Journal of Clinical and Experimental Medicine, 7(10), 3181–3192.PubMedPubMedCentral

97.

Jiang, Y., & Zhan, H. (2020). Communication between EMT and PD-L1 signaling: New insights into tumor immune evasion. Cancer Letters, 468, 72–81.PubMed

98.

Noman, M. Z., Janji, B., Abdou, A., Hasmim, M., Terry, S., Tan, T. Z., Mami-Chouaib, F., Thiery, J. P., & Chouaib, S. (2017). The immune checkpoint ligand PD-L1 is upregulated in EMT-activated human breast cancer cells by a mechanism involving ZEB-1 and miR-200. Oncoimmunology, 6(1), e1263412.PubMedPubMedCentral

99.

Mathew, M., Safyan, R. A., & Shu, C. A. (2017). PD-L1 as a biomarker in NSCLC: Challenges and future directions. Annals of Translational Medicine, 5(18), 375.PubMedPubMedCentral

100.

Kim, S., Koh, J., Kim, M. Y., Kwon, D., Go, H., Kim, Y. A., Jeon, Y. K., & Chung, D. H. (2016). PD-L1 expression is associated with epithelial-to-mesenchymal transition in adenocarcinoma of the lung. Human Pathology, 58, 7–14.PubMed

101.

Ock, C. Y., Kim, S., Keam, B., Kim, M., Kim, T. M., Kim, J. H., Jeon, Y. K., Lee, J. S., Kwon, S. K., Hah, J. H., Kwon, T. K., Kim, D. W., Wu, H. G., Sung, M. W., & Heo, D. S. (2016). PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma. Oncotarget, 7(13), 15901–15914.PubMedPubMedCentral

102.

Tsutsumi, S., Saeki, H., Nakashima, Y., Ito, S., Oki, E., Morita, M., Oda, Y., Okano, S., & Maehara, Y. (2017). Programmed death-ligand 1 expression at tumor invasive front is associated with epithelial-mesenchymal transition and poor prognosis in esophageal squamous cell carcinoma. Cancer Science, 108(6), 1119–1127.PubMedPubMedCentral

103.

Qiu, X. Y., Hu, D. X., Chen, W. Q., Chen, R. Q., Qian, S. R., Li, C. Y., Li, Y. J., Xiong, X. X., Liu, D., Pan, F., Yu, S. B., & Chen, X. Q. (2018). PD-L1 confers glioblastoma multiforme malignancy via Ras binding and Ras/Erk/EMT activation. Biochimica et biophysica acta. Molecular Basis of Disease, 1864(5 Pt A), 1754–1769.PubMed

104.

Alsuliman, A., Colak, D., Al-Harazi, O., Fitwi, H., Tulbah, A., Al-Tweigeri, T., Al-Alwan, M., & Ghebeh, H. (2015). Bidirectional crosstalk between PD-L1 expression and epithelial to mesenchymal transition: Significance in claudin-low breast cancer cells. Molecular Cancer, 14, 149.PubMedPubMedCentral

105.

Bouillez, A., Rajabi, H., Jin, C., Samur, M., Tagde, A., Alam, M., Hiraki, M., Maeda, T., Hu, X., Adeegbe, D., Kharbanda, S., Wong, K. K., & Kufe, D. (2017). MUC1-C integrates PD-L1 induction with repression of immune effectors in non-small-cell lung cancer. Oncogene, 36(28), 4037–4046.PubMedPubMedCentral

106.

Maeda, T., Hiraki, M., Jin, C., Rajabi, H., Tagde, A., Alam, M., Bouillez, A., Hu, X., Suzuki, Y., Miyo, M., Hata, T., Hinohara, K., & Kufe, D. (2018). MUC1-C induces PD-L1 and immune evasion in triple-negative breast cancer. Cancer research, 78(1), 205–215.PubMed

107.

Kumar, S., Davra, V., Obr, A. E., Geng, K., Wood, T. L., De Lorenzo, M. S., & Birge, R. B. (2017). Crk adaptor protein promotes PD-L1 expression, EMT and immune evasion in a murine model of triple-negative breast cancer. Oncoimmunology, 7(1), e1376155.PubMedPubMedCentral

108.

Suda, K., Rozeboom, L., Rivard, C. J., Yu, H., Ellison, K., Melnick, M. A. C., Hinz, T. K., Chan, D., Heasley, L. E., Politi, K., Mitsudomi, T., & Hirsch, F. R. (2017). Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cells. Lung Cancer (Amsterdam, Netherlands), 109, 1–8.PubMed

109.

Martinez-Ciarpaglini, C., Oltra, S., Roselló, S., Roda, D., Mongort, C., Carrasco, F., Gonzalez, J., Santonja, F., Tarazona, N., Huerta, M., Espí, A., Ribas, G., Ferrández, A., Navarro, S., & Cervantes, A. (2019). Low miR200c expression in tumor budding of invasive front predicts worse survival in patients with localized colon cancer and is related to PD-L1 overexpression. Modern Pathology, Inc, 32(2), 306–313.

110.

Ding, X., Ji, J., Jiang, J., Cai, Q., Wang, C., Shi, M., Yu, Y., Zhu, Z., & Zhang, J. (2018). HGF-mediated crosstalk between cancer-associated fibroblasts and MET-unamplified gastric cancer cells activates coordinated tumorigenesis and metastasis. Cell Death & Disease, 9(9), 867.

111.

Dong, Y., Zheng, Q., Wang, Z., Lin, X., You, Y., Wu, S., Wang, Y., Hu, C., Xie, X., Chen, J., Gao, D., Zhao, Y., Wu, W., Liu, Y., Ren, Z., Chen, R., & Cui, J. (2019). Higher matrix stiffness as an independent initiator triggers epithelial-mesenchymal transition and facilitates HCC metastasis. Journal of Hematology & Oncology, 12(1), 112.

112.

Zhang, K., Corsa, C. A., Ponik, S. M., Prior, J. L., Piwnica-Worms, D., Eliceiri, K. W., Keely, P. J., & Longmore, G. D. (2013). The collagen receptor discoidin domain receptor 2 stabilizes SNAIL1 to facilitate breast cancer metastasis. Nature Cell Biology, 15(6), 677–687.PubMedPubMedCentral

113.

Sim, W. J., Iyengar, P. V., Lama, D., Lui, S. K. L., Ng, H. C., Haviv-Shapira, L., Domany, E., Kappei, D., Tan, T. Z., Saei, A., Jaynes, P. W., Verma, C. S., Kumar, A. P., Rouanne, M., Ha, H. K., Radulescu, C., Ten Dijke, P., Eichhorn, P. J. A., & Thiery, J. P. (2019). c-Met activation leads to the establishment of a TGFβ-receptor regulatory network in bladder cancer progression. Nature Communications, 10(1), 4349.PubMedPubMedCentral

114.

Glodde, N., Bald, T., van den Boorn-Konijnenberg, D., Nakamura, K., O'Donnell, J. S., Szczepanski, S., Brandes, M., Eickhoff, S., Das, I., Shridhar, N., Hinze, D., Rogava, M., van der Sluis, T. C., Ruotsalainen, J. J., Gaffal, E., Landsberg, J., Ludwig, K. U., Wilhelm, C., Riek-Burchardt, M., et al. (2017). Reactive neutrophil responses dependent on the receptor tyrosine kinase c-MET limit cancer immunotherapy. Immunity, 47(4), 789–802.e9.PubMed

115.

Jing, X., Yang, F., Shao, C., Wei, K., Xie, M., Shen, H., & Shu, Y. (2019). Role of hypoxia in cancer therapy by regulating the tumor microenvironment. Molecular Cancer, 18(1), 157.PubMedPubMedCentral

116.

Hou, P. C., Li, Y. H., Lin, S. C., Lin, S. C., Lee, J. C., Lin, B. W., Liou, J. P., Chang, J. Y., Kuo, C. C., Liu, Y. M., Sun, H. S., & Tsai, S. J. (2017). Hypoxia-induced downregulation of DUSP-2 phosphatase drives colon cancer stemness. Cancer Research, 77(16), 4305–4316.PubMed

117.

Calin, G. A., & Pardini, B. (2019). Mir-roring hypoxia in EGFR-TKI tolerance. Nature Metabolism, 1(4), 418–419.PubMed

118.

Ye, Y., Hu, Q., Chen, H., Liang, K., Yuan, Y., Xiang, Y., Ruan, H., Zhang, Z., Song, A., Zhang, H., Liu, L., Diao, L., Lou, Y., Zhou, B., Wang, L., Zhou, S., Gao, J., Jonasch, E., Lin, S. H., et al. (2019). Characterization of hypoxia-associated molecular features to aid hypoxia-targeted therapy. Nature Metabolism, 1(4), 431–444.PubMedPubMedCentral

119.

Gonzalez, D. M., & Medici, D. (2014). Signaling mechanisms of the epithelial-mesenchymal transition. Science Signaling, 7(344), re8.PubMedPubMedCentral

120.

Sahlgren, C., Gustafsson, M. V., Jin, S., Poellinger, L., & Lendahl, U. (2008). Notch signaling mediates hypoxia-induced tumor cell migration and invasion. Proceedings of the National Academy of Sciences of the United States of America, 105(17), 6392–6397.PubMedPubMedCentral

121.

Schito, L., & Semenza, G. L. (2016). Hypoxia-inducible factors: Master regulators of cancer progression. Trends in Cancer, 2(12), 758–770.PubMed

122.

Wang, J., Tian, L., Khan, M. N., Zhang, L., Chen, Q., Zhao, Y., Yan, Q., Fu, L., & Liu, J. (2018). Ginsenoside Rg3 sensitizes hypoxic lung cancer cells to cisplatin via blocking of NF-κB mediated epithelial-mesenchymal transition and stemness. Cancer Letters, 415, 73–85.PubMed

123.

Qin, Y., Liu, H. J., Li, M., Zhai, D. H., Tang, Y. H., Yang, L., Qiao, K. L., Yang, J. H., Zhong, W. L., Zhang, Q., Liu, Y. R., Yang, G., Sun, T., & Yang, C. (2018). Salidroside improves the hypoxic tumor microenvironment and reverses the drug resistance of platinum drugs via HIF-1α signaling pathway. EBioMedicine, 38, 25–36.PubMedPubMedCentral

124.

Spranger, S., Bao, R., & Gajewski, T. F. (2015). Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature, 523(7559), 231–235.PubMed

125.

Spranger, S., Dai, D., Horton, B., & Gajewski, T. F. (2017). Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy. Cancer Cell, 31(5), 711–723.e4.PubMedPubMedCentral

126.

George, S., Miao, D., Demetri, G. D., Adeegbe, D., Rodig, S. J., Shukla, S., Lipschitz, M., Amin-Mansour, A., Raut, C. P., Carter, S. L., Hammerman, P., Freeman, G. J., Wu, C. J., Ott, P. A., Wong, K. K., & Van Allen, E. M. (2017). Loss of PTEN is associated with resistance to anti-PD-1 checkpoint blockade therapy in metastatic uterine leiomyosarcoma. Immunity, 46(2), 197–204.PubMedPubMedCentral

127.

Terry, S., Faouzi Zaarour, R., Hassan Venkatesh, G., Francis, A., El-Sayed, W., Buart, S., Bravo, P., Thiery, J., & Chouaib, S. (2018). Role of hypoxic stress in regulating tumor immunogenicity, resistance and plasticity. International Journal of Molecular Sciences, 19(10), 3044.PubMedPubMedCentral

128.

Malek, R., Wang, H., Taparra, K., & Tran, P. T. (2017). Therapeutic targeting of epithelial plasticity programs: focus on the epithelial-mesenchymal transition. Cells, Tissues, Organs, 203(2), 114–127.PubMed

129.

Holmgaard, R. B., Schaer, D. A., Li, Y., Castaneda, S. P., Murphy, M. Y., Xu, X., Inigo, I., Dobkin, J., Manro, J. R., Iversen, P. W., Surguladze, D., Hall, G. E., Novosiadly, R. D., Benhadji, K. A., Plowman, G. D., Kalos, M., & Driscoll, K. E. (2018). Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade. Journal For Immunotherapy of Cancer, 6(1), 47.PubMedPubMedCentral

130.

Sow, H. S., Ren, J., Camps, M., Ossendorp, F., & Ten Dijke, P. (2019). Combined inhibition of TGF-β signaling and the PD-L1 immune checkpoint is differentially effective in tumor models. Cells, 8(4), 320.PubMedPubMedCentral

131.

Yang, Y., Xu, W., Peng, D., Wang, H., Zhang, X., Wang, H., Xiao, F., Zhu, Y., Ji, Y., Gulukota, K., Helseth, D. L., Jr., Mangold, K. A., Sullivan, M., Kaul, K., Wang, E., Prabhakar, B. S., Li, J., Wu, X., Wang, L., & Seth, P. (2019). An oncolytic adenovirus targeting transforming growth factor β inhibits protumorigenic signals and produces immune activation: A novel approach to enhance anti-PD-1 and anti-CTLA-4 therapy. Human gene therapy, 30(9), 1117–1132.PubMedPubMedCentral

132.

Dodagatta-Marri, E., Meyer, D. S., Reeves, M. Q., Paniagua, R., To, M. D., Binnewies, M., Broz, M. L., Mori, H., Wu, D., Adoumie, M., Del Rosario, R., Li, O., Buchmann, T., Liang, B., Malato, J., Arce Vargus, F., Sheppard, D., Hann, B. C., Mirza, A., et al. (2019). α-PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by α-TGFβ antibody to promote durable rejection and immunity in squamous cell carcinomas. Journal for Immunotherapy of Cancer, 7(1), 62.PubMedPubMedCentral

133.

Knudson, K. M., Hicks, K. C., Luo, X., Chen, J. Q., Schlom, J., & Gameiro, S. R. (2018). M7824, a novel bifunctional anti-PD-L1/TGFβ Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine. Oncoimmunology, 7(5), e1426519.PubMedPubMedCentral

134.

Lan, Y., Zhang, D., Xu, C., Hance, K. W., Marelli, B., Qi, J., Yu, H., Qin, G., Sircar, A., Hernández, V. M., Jenkins, M. H., Fontana, R. E., Deshpande, A., Locke, G., Sabzevari, H., Radvanyi, L., & Lo, K. M. (2018). Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β. Science Translational Medicine, 10(424), eaan5488.PubMed

135.

Grenga, I., Donahue, R. N., Gargulak, M. L., Lepone, L. M., Roselli, M., Bilusic, M., & Schlom, J. (2018). Anti-PD-L1/TGFβR2 (M7824) fusion protein induces immunogenic modulation of human urothelial carcinoma cell lines, rendering them more susceptible to immune-mediated recognition and lysis. Urologic Oncology, 36(3), 93.e1–93.e11.PubMed

136.

Strauss, J., Heery, C. R., Schlom, J., Madan, R. A., Cao, L., Kang, Z., Lamping, E., Marté, J. L., Donahue, R. N., Grenga, I., Cordes, L., Christensen, O., Mahnke, L., Helwig, C., & Gulley, J. L. (2018). Phase I trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGFβ, in advanced solid tumors. Clinical Cancer Research, 24(6), 1287–1295.PubMedPubMedCentral

137.

Kang, S. H., Keam, B., Ahn, Y. O., Park, H. R., Kim, M., Kim, T. M., Kim, D. W., & Heo, D. S. (2018). Inhibition of MEK with trametinib enhances the efficacy of anti-PD-L1 inhibitor by regulating anti-tumor immunity in head and neck squamous cell carcinoma. Oncoimmunology, 8(1), e1515057.PubMedPubMedCentral

138.

Hellmann, M. D., Kim, T. W., Lee, C. B., Goh, B. C., Miller, W. H., Jr., Oh, D. Y., Jamal, R., Chee, C. E., Chow, L. Q. M., Gainor, J. F., Desai, J., Solomon, B. J., Das Thakur, M., Pitcher, B., Foster, P., Hernandez, G., Wongchenko, M. J., Cha, E., Bang, Y. J., et al. (2019). Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors. Annals of Oncology, 30(7), 1134–1142.PubMedPubMedCentral

139.

Singh, D., Khan, M. A., & Siddique, H. R. (2020). Emerging role of long non-coding RNAs in cancer chemoresistance: unravelling the multifaceted role and prospective therapeutic targeting. Molecular Biology Reports, 47(7), 5569–5585.PubMed

140.

Singh, D., Kesharwani, P., Alhakamy, N. A., & Siddique, H. R. (2022). Accentuating CircRNA-miRNA-transcription factors axis: A conundrum in cancer research. Frontiers in Pharmacology, 12, 784801.PubMedPubMedCentral

141.

Singh, D., Khan, M. A., & Siddique, H. R. (2023). Role of epigenetic drugs in sensitizing cancers to anticancer therapies: emerging trends and clinical advancements. Epigenomics, 15(8), 517–537.PubMed

Titel: Epithelial-to-mesenchymal transition in cancer progression: unraveling the immunosuppressive module driving therapy resistance
verfasst von: Deepti Singh
Hifzur R. Siddique
Publikationsdatum: 30.09.2023
Verlag: Springer US
Erschienen in: Cancer and Metastasis Reviews / Ausgabe 1/2024
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-023-10141-y

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Epithelial-to-mesenchymal transition in cancer progression: unraveling the immunosuppressive module driving therapy resistance

Abstract

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2024

The emerging role of the gut microbiome in cancer cell plasticity and therapeutic resistance

Harnessing function of EMT in cancer drug resistance: a metastasis regulator determines chemotherapy response

Biographies

Preface

B7-H3 at the crossroads between tumor plasticity and colorectal cancer progression: a potential target for therapeutic intervention

Dynamic interplay of nuclear receptors in tumor cell plasticity and drug resistance: Shifting gears in malignant transformations and applications in cancer therapeutics

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie